Neal D. Shore, MD, FACS | Authors

June 29, 2021

During a discussion at 2021 ASCO, Neal D. Shore, MD, said he was most excited to see data from the phase 3 VISION trial of lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer.

June 21, 2021

Neal D. Shore, MD, FACS, discusses the importance of multidisciplinary care for patients with advanced prostate cancer.

July 01, 2020

Results showed that once daily relugolix established superiority over leuprolide and reduced the incidence of major cardiovascular events.

June 04, 2020

The Carolina Urologic Research Center expert discusses the benefits of oral relugolix for patients with prostate cancer.

July 15, 2015

In this interview we discuss recent trials that looked at the use of upfront chemotherapy combined with androgen deprivation therapy in men with metastatic prostate cancer and how they have changed clinical practice.

February 15, 2014

In this article, we review recent advances in the discovery of prostate cancer biomarkers, their integration into clinical practice, and implications for improving clinical management of the disease.

November 15, 2013

I have read multiple overviews of the current management of castration-resistant prostate cancer (CRPC). These articles have very adeptly summarized the key trials leading to a multitude of US Food and Drug Administration (FDA) approvals of new agents for men with CRPC.